Dybly Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Liquidation

Dybly General Information

Description

Operator of a pharmaceutical company intended to support patients with inflammatory and fibrotic diseases. The company offers molecules with activity and safety profiles backed by hypothesis-driven small-molecule drug design validated by empirical data, enabling patients with fibrotic diseases, blood cancer, and rheumatoid arthritis to receive improved treatment.

Contact Information

Website
www.dybly.com
Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Corporate Office
  • Im Erasmushaus
  • Baeumleingasse 18
  • 4051 Basel
  • Switzerland
Primary Industry
Distributors (Healthcare)
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Im Erasmushaus
  • Baeumleingasse 18
  • 4051 Basel
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dybly Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Bankruptcy: Liquidation 26-Nov-2025 Completed Bankruptcy: Liquidation
3. Angel (individual) 21-Oct-2020 Completed Generating Revenue
2. Angel (individual) 25-Feb-2008 $510K $510K Completed Startup
1. Angel (individual) 01-Dec-2006 Completed Startup
To view Dybly’s complete valuation and funding history, request access »

Dybly Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 19,444 $0.119843 $16.81 $16.81 1x $16.81 1.19%
To view Dybly’s complete cap table history, request access »

Dybly Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Dybly Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2019238557-A1 Preparation of condensed triazepine derivatives and their use as bet inhibitors Inactive 13-Jun-2018
WO-2010049466-A1 Thienotriazolodiazepine derivatives active on apo a Inactive 30-Oct-2008
US-20090004121-A1 Combination of picotamide with nafronyl Inactive 28-Jun-2007
WO-2009000907-A2 Combination of picotamide with nafronyl Inactive 28-Jun-2007
WO-2009000907-A3 Combination of picotamide with nafronyl Inactive 28-Jun-2007 A61K31/341
To view Dybly’s complete patent history, request access »

Ready to get started?

Request a free trial

Dybly FAQs

  • When was Dybly founded?

    Dybly was founded in 2006.

  • Where is Dybly headquartered?

    Dybly is headquartered in Basel, Switzerland.

  • What industry is Dybly in?

    Dybly’s primary industry is Distributors (Healthcare).

  • Is Dybly a private or public company?

    Dybly is a Private company.

  • What is Dybly’s current revenue?

    The current revenue for Dybly is .

  • How much funding has Dybly raised over time?

    Dybly has raised $644K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process